Drug
Trb191
Trb191: highest development phase Phase 1, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| TRB191 NCT07908667 | Phase 1 | Extensive-stage Small Cell Lung Cancer |
Latest
No recent events.
Follow Trb191 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.